

## Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics

The National Institutes of Health (NIH) hereby announces the BPCA Priority List of Needs in Pediatric Therapeutics for 2017-2018.

### Update on BPCA Prioritization

The BPCA requires that the NIH, in consultation with the Food and Drug Administration (FDA) and experts in pediatric research, develop and publish a priority list of needs in pediatric therapeutics. Part of fulfilling the NIH's authority and responsibility outlined in the BPCA legislation is to establish a program for pediatric drug testing and development and to publish a list of needs in pediatric therapeutics. The BPCA Priority List consists of key therapeutic needs in the medical treatment of children and adolescents; it is organized by therapeutic area, which can be a group of conditions, or a setting of care, or a subgroup of the population.

The implementation of the BPCA prioritization process included the following: initial outreach to solicit input from experts in pediatric medicine to gather information on drugs and therapeutic areas that need further study; data gathering through literature reviews, symposia, and specified therapeutic area working groups; and the enhancement of knowledge and resources through NIH and US Department of Health and Human Services (HHS)-interagency wide collaborations.

Below is an update of the priority list developments to date:

- Annually, the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) reaches out to experts in pediatrics to identify needs in pediatric therapeutics.
- All nominations received by the NICHD are reviewed, considered, and evaluated according to six key criteria:
  - Relevance to BPCA mission and goals
  - No disqualifying ethical concerns
  - Level of evidence available and current gaps
  - Potential impact on children, society, and delivery of care
  - Consideration of the different populations that may benefit from the research
  - Feasibility and availability of the resources needed to conduct the study.
- Minutes of all previous BPCA therapeutic area working group meetings and other collaborations can be found on the BPCA Web site.  
[https://bpcanichd.nih.gov/prioritization/working\\_groups/Pages/annual-prioritization.aspx](https://bpcanichd.nih.gov/prioritization/working_groups/Pages/annual-prioritization.aspx)
- Information on the current BPCA clinical trials can be found on the PTN website.  
<https://www.pediatrictrials.org/ptn-studies>

Below is an updated list (**in bold**) of therapeutic areas and drugs that have been prioritized for study for 2017-2018. The list also includes all prioritized areas and drugs since the inception of the BPCA. A summary of the NICHD's plans and progress in all of areas prioritized to date is also provided.

## Priority List of Needs in Pediatric Therapeutics 2017-2018

In accordance with the BPCA legislation, the following list outlines priority needs in pediatric therapeutics for the therapeutic areas listed below.

- [Table 1: Infectious Disease Priorities](#)
- [Table 2: Cardiovascular Disease Priorities](#)
- [Table 3: Respiratory Disease Priorities](#)
- [Table 4: Intensive Care Priorities](#)
- [Table 5: Biodefense Research Priorities](#)
- [Table 6: Pediatric Cancer Priorities](#)
- [Table 7: Psychiatric Disorder Priorities](#)
- [Table 8: Neurological Disease Priorities](#)
- [Table 9: Neonatal Research Priorities](#)
- [Table 10: Adolescent Research Priorities](#)
- [Table 11: Hematologic Disease Priorities](#)
- [Table 12: Endocrine Disease Priorities and Diseases with Limited Alternative Therapies](#)
- [Table 13: Dermatologic Disease Priorities](#)
- [Table 14: Gastrointestinal Disease Priorities](#)
- [Table 15: Renal Disease Priorities](#)
- [Table 16: Rheumatologic Disease Priorities](#)
- [Table 17: Special Considerations](#)

**Table 1. Infectious Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Skin and Soft Tissue Infections	Clindamycin	Optimal therapy and management of community-acquired skin and soft tissue infections	Pharmacokinetics (PK), safety, and efficacy clinical studies, particularly in overweight and obese children	Multiple pediatric studies by the Pediatric Trials Network (PTN)*  <b>Clinical study report (CSR) submitted to FDA for clindamycin use in obese patients submitted to FDA in October 2015. FDA docket submission in November 2016</b>
	Trimethoprim-sulfamethoxazole	Biomarkers of disease	PK and efficacy (comparison) studies in normal weight and obese children	Pediatric studies performed by the PTN.  CSR finalization underway. Submission to the FDA anticipated Spring 2017
Pediatric Infections	Doxycycline	PK, safety in children younger than 8 years	PK, safety, and efficacy clinical studies in normal weight and obese children	Pediatric opportunistic study performed by the PTN.  <b>CSR finalization complete. Submission to the FDA January 2017</b>
	Isavuconazole	<b>PK, safety and efficacy data in immunocompromised children to treat serious fungal infections</b>	<b>PK, safety and pharmacodynamic (PD) clinical studies</b>	<b>Under consideration</b>
	Daptomycin	<b>PK and safety studies in young children for invasive gram-positive infections</b>	<b>Dosing and safety studies in children &lt; 2 years</b>	<b>Under consideration</b>
Tinea capitis	Griseofulvin	Safety and efficacy of higher doses in children < 20 kg with tinea capitis	PK, efficacy, and safety of higher doses in young children	Written Request (WR) received from the FDA  Pediatric opportunistic study by the PTN ongoing

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Infections in neonates	Metronidazole	PK and efficacy in neonates with abdominal infections	PK study	Pediatric PK study completed by the PTN; CSR submitted to the FDA in October 2012. Follow-up study underway
	Acyclovir	Dosing, efficacy, and safety in neonates and infants with herpetic infections	PK, safety, and efficacy clinical studies in neonates and children	Pediatric PK and safety study performed by the PTN <b>CSR submitted to the FDA for review in August 2016</b>
	Ampicillin	PK and safety in very low birth weight neonates	PK, safety clinical studies in neonates	WR received from the FDA <b>CSR submitted to the FDA in December 2014. FDA docket submissions in October 2015 and October 2016</b>
	Fluconazole	Dosing and safety in very low birth weight neonates	PK, safety clinical studies in neonates	Pediatric PK and safety study completed by the PTN <b>CSR submitted to the FDA in January 2015.</b>
	<b>Valganciclovir</b>	<b>PK and safety in infants exposed to CMV</b>	<b>Optimal PK-PD endpoints to assess efficacy and safety</b>	<b>Under consideration</b>
	<b>#Clindamycin Rifampin Gentamicin</b>	<b>PK and safety of antibiotics used in pre-term and term neonates to treat various infections</b>		<b>Pediatric PK and safety studies underway by PTN.</b>
Influenza	Oseltamivir	Pharmaco-epidemiology data	Impact on clinical outcomes in hospitalized children with influenza	NICHD grant funded and completed. <a href="https://bpca.nichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx">https://bpca.nichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx</a> Pediatric opportunistic study under review by the PTN.

Drug and indications **in bold** have been identified by the NICHD as a new priority and have been added to the BPCA list. #Drugs listed twice for different indications or populations.

\*Please refer to the PTN website for more details ([www.pediatrictrials.org](http://www.pediatrictrials.org))

**Table 2. Cardiovascular Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Pediatric Hypertension	#Hydrochlorothiazide	PK, safety, and efficacy in obese adolescents	Comparison studies, PK studies	Pediatric opportunistic study by the PTN ongoing
	#Beta blockers	PK, safety, and efficacy in obese adolescents	Comparison studies, PK studies	Pediatric opportunistic study under review by the PTN.
	Lisinopril	PK in children with kidney transplant	PK, safety, and efficacy clinical studies; formulations	Pediatric PK and safety study in renal transplant patients completed by the PTN  Clinical study Report (CSR) submitted to the FDA December 2014.  <b>Label change in effect as of April 2016.</b>
	Calcium channel blockers	PK in children with kidney transplantation, formulations	PK, safety, and efficacy clinical studies	Pediatric opportunistic study under review by the PTN.
	<b>No specific drug</b>	<b>Treatment options and biomarkers of end organ damage</b>	<b>Biomarkers of disease progression and Long-term follow up studies</b>	Co-funding with the Health Resources and Services Administration (HRSA) grant # UA6MC15585 to determine frequency of medication use via electronic health records (EHR) with the Pediatric Research in the Office Setting (PROS) Network <a href="https://www.ncbi.nlm.nih.gov/pubmed/27940711">https://www.ncbi.nlm.nih.gov/pubmed/27940711</a>  <b>Workshop Fall 2017. Collaboration between NICHD, FDA, NHLBI</b>
	Sodium nitroprusside	PK, safety, and efficacy	PK, short- and long-term safety and efficacy trials for controlled hypotension	WR received from the FDA; CSR to the FDA August 2012  Redacted data submitted to the FDA docket in April and September 2012  <b>Label change in effect as of December 2013</b>
	<b>Hydralazine (Intravenous)</b>	<b>Limited therapeutic options</b>	<b>Dosing and safety studies of intermittent use in children</b>	<b>Under consideration</b>

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Hypotension	Dopamine	Outcome measures in neonates and children treated for hypotension	Defining outcome measures	Collaboration with existing NICHD network (Neonatal Research Network) Clinical Trial #NCT00874393  Publication: Pediatrics 2013 Jun 6;131(6):e1865-73. Epub 2013 May 6.
	Epinephrine	Dosage in resuscitation in children with elevated body mass index	PK studies	Pediatric opportunistic study by the PTN ongoing
Dyslipidemia	Statins	Risk/benefit profile of long-term use in children	Novel study designs, use of surrogate markers for determining the value of long-term statin use in children	Pediatric opportunistic study by the PTN under review

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.  
#Drugs listed twice for different indications or populations.

**Table 3. Respiratory Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Asthma	Asthma therapeutics in young children	Objective measures of lung function and responses to therapy in children younger than 4 years	<p>Identification of barriers to implementation of guidelines for asthma treatment</p> <p>Standardization of outcome measures in research</p> <p><b>Identifying pharmacodynamics markers of treatment effects</b></p>	<p>Trans-NIH and trans-U.S. Department of Health and Human Services (HHS) collaborations</p> <p>Asthma Outcome Measures meeting March 2010; published in the Supplement to <i>The Journal of Allergy and Clinical Immunology</i>, Volume 129, No. 3. March 2012</p> <p>Co-funding with the HRSA grant # UA6MC15585 to determine frequency of medication use via EHR with the PROS Network</p> <p><b>NICHD sponsoring biomarkers working group</b></p>
	Albuterol	Dose response, safety, and efficacy	Safety, efficacy, and appropriate mode of delivery in children in acute care settings	NICHD Collaborative Pediatric Critical Care Network data collection completed. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22494876">https://www.ncbi.nlm.nih.gov/pubmed/22494876</a>
Pulmonary hypertension	Sildenafil	Treatment strategies and outcome measures in children with pulmonary hypertension of differing etiologies	<p>PK and pharmacodynamics studies in neonates receiving the drug</p> <p>Epidemiology of differing etiologies and age appropriate outcome measures in children</p>	<p>Pediatric observational and PK study by the PTN ongoing</p> <p><b>Novel formulations, pre-clinical data, and clinical PK and safety protocol underway by PTN</b></p>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 4. Intensive Care Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Anesthesia/sedation	#Ketamine	Safety	Preclinical and clinical studies of short- and long-term effects	Preclinical studies completed with the FDA/ National Center for Toxicological Research (NCTR) via Inter-Agency Agreement <a href="https://bpcanichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx">https://bpcanichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx</a> Pediatric opportunistic study by the PTN ongoing
	Inhaled anesthetics	Toxicity of inhaled anesthetics in developing brains	Identification of markers of apoptosis	Preclinical studies completed with the FDA/ National Center for Toxicological Research (NCTR) via Inter-Agency Agreement <a href="https://bpcanichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx">https://bpcanichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx</a> Publication: Journal of Applied Toxicology 09/2013; 33(9). DOI:10.1002/jat.2857
	#Lorazepam	Dosing, safety	PK, safety, and efficacy trial comparing lorazepam with midazolam for sedation	WR received from the FDA Clinical trial completed; CSR under review
	<b>Dexmedetomidine</b>	<b>Adjunctive use in pediatric anesthesia</b>	<b>Long-term follow up</b>	<b>Under consideration</b>
<b>Shock</b>	<b>Hydrocortisone</b>	<b>Dosing, duration of treatment, weaning process</b>	<b>PK and comparative effectiveness studies</b>	<b>Under consideration</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

#Drugs listed twice for different indications or populations.



**Table 5. Biodefense Research Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Nerve agent exposure	Drug delivery systems	Need for pediatric auto-injectors	Availability and validation	Trans-HHS collaborations
	Midazolam	Dosing studies for treatment of seizures and in obese children	PK studies	Trans-NIH collaborations PTN study completed. Manuscript in development
Cyanide toxicity	Hydroxycobalamin	Dosing and effectiveness in inhalation injuries suffered during fires	Safety and efficacy	Pediatric opportunistic study by the PTN ongoing; real-time cyanide assay developed in collaboration with NINDS <a href="https://www.ncbi.nlm.nih.gov/pubmed/23653045">https://www.ncbi.nlm.nih.gov/pubmed/23653045</a>
Organophosphate poisoning	Pralidoxime	Dosing and safety		<b>Label changed September 2010</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 6. Pediatric Cancer Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Neuroblastoma	13-cis-retinoic acid	New indication for neuroblastoma, pediatric formulation	PK studies, new formulation	Proposed Pediatric Study Request negotiated with the FDA; WR issued and declined by manufacturer and received from the FDA  Collaboration with National Cancer Institute (NCI)/Children's Oncology Group (COG)  Study complete, findings under review, and analyses ongoing
Leukemias and solid tumors	#Methotrexate	Safety studies	Neurocognitive outcomes in young children with high-risk acute lymphoblastic leukemia	WR received from the FDA  Collaborations with NCI/COG; clinical trial ongoing
	Vincristine	PK and safety studies	PK modeling and safety studies to evaluate for neurotoxicity	WR received from the FDA  Collaborations with NCI/COG; clinical trial completed; data analysis ongoing  Clinical and Translational Science Awards (CTSA) administrative supplement awarded to evaluate methods of determining neurotoxicity
	Daunomycin	PK studies	PK studies in children with elevated body mass index	WR received from the FDA  Collaborations with NCI/COG; study completed; CSR under development
	Actinomycin-D	PK and safety studies	PK modeling and simulation, data mining for safety (hepatotoxicity)	WR received from the FDA  Collaborations with NCI/COG; clinical trial completed; data analysis ongoing

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.  
#Drugs listed twice for different indications or populations.

**Table 7. Psychiatric Disorder Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Attention deficit and hyperactivity disorder (ADHD)	Methylphenidate	Safety and toxicity		Preclinical and clinical studies with NCTR and the National Institute of Environmental Health Sciences  Publication: PLoS ONE 09/2014; 9(9):e106101. DOI:10.1371/journal.pone.0106101
Bipolar disease	Lithium	PK, safety, and efficacy	Dosing and tolerance, short- and long-term safety	WR received from the FDA  PK data submitted to the FDA January 2010; safety and efficacy clinical trial completed April 2013  CSR submitted to FDA in winter 2015. Awaiting FDA final review
Psychosis, aggression	Atypical antipsychotics:  Risperidone  Aripiprazole	Long-term safety—metabolic derangements  Pharmacoepidemiology studies	Comparative long-term safety, epidemiology research on frequency of use	Translational research; co-funding with HRSA grant # UA6MC15585 to determine frequency of use via electronic health records (EHR) with the (PROS) Network Publication in Pediatrics scheduled for 6/22/2015  PTN opportunistic study complete  <b>New safety study of select antipsychotics in development for anticipated launch in Spring 2018</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 8. Neurological Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Cerebral palsy	Baclofen (oral)	PK, safety, and efficacy	PK and efficacy, pediatric formulation	WR received from the FDA  Clinical trial completed; CSR submitted to the FDA December 2013
Migraines	No specific drug	Efficacy in prophylaxis	Efficacy in migraine prevention	NICHD co-fund of migraine clinical trial with NINDS grant number U01NS-076788 completed 2015.
	Amitriptyline	Efficacy in prophylaxis	Efficacy in migraine prevention	Under consideration
Seizures	#Lorazepam	PK, safety, and efficacy	PK, safety, and efficacy in treating status epilepticus	WR received from the FDA  PK trial data submitted to the FDA February 2009; safety and efficacy clinical trial completed  CSR submitted to the FDA in October 2014 and May 2015.  <b>Label changed as of June 2016</b>
	Fosphenytoin	PK, safety	PK, safety in treating seizures in young children	Under consideration
	Diazepam	PK, safety, and efficacy	PK, safety in treating seizures in children of all ages	CSR submitted to FDA in January 2017 for potential label change
	<b>Levetiracetam Valproic Acid Topiramate Oxcarbazepine</b>	<b>Dosing and safety studies in younger children</b>	<b>Establishing body weight-clearance relationship in children</b>	<b>Pediatric dosing studies of the steady state PK of anti-epileptics in obese children in development by PTN</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

#Drugs listed twice for different indications or populations.

**Table 9. Neonatal Research Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Neonatal bronchopulmonary dysplasia (BPD)/lung development	Betamethasone	Dosing, efficacy	Determination of dosing and effectiveness	Reviewing existing data
	Azithromycin (IV)	Dosing, efficacy	PK, efficacy in treating ureaplasma infections to prevent BPD	WR received from the FDA; NICHD grant # HD056424 funding complete; HD067126 ongoing <a href="https://bpc.nichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx">https://bpc.nichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx</a>
	#Hydrochlorothiazide	Dosing, safety, and efficacy	Determination of dosing and effectiveness	Pediatric opportunistic study by the PTN underway  Collaboration with the NHLBI Prematurity and Respiratory Outcomes Program (PROP) network data collection ongoing NCT01435187
	Furosemide	Dosing and safety	Determination of dosing and safety in preterm neonates	Opportunistic PTN study and retrospective analysis of diuretics in children complete  <b>PK and safety study underway with collaboration with PROP Network for additional data collection.</b>
Neonatal pain	Morphine	Dosing	Optimization of dosing and biomarkers of pain in neonates	WR received from the FDA  Current NICHD grant #HD048689 funded and completed  <a href="https://bpc.nichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx">https://bpc.nichd.nih.gov/prioritization/clinicaltrials/Pages/pediatric-trials-network.aspx</a>
	<b>Hydromorphone</b> <b>#Ketamine</b>	<b>Dosing</b>	<b>Optimization of dosing and biomarkers of pain in neonates</b>	<b>Pediatric opportunistic study by the PTN in development</b>
Neonatal abstinence syndrome (NAS)	Metadone	PK, safety	Treatment strategies of NAS in opioid-exposed neonates	CTSA administrative supplement completed  PTN PK study completed. CSR development underway. FDA submission pending

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Neonatal necrotizing enterocolitis (NEC)	Meropenem	PK, safety in neonates		WR received from the FDA  Clinical PK and safety trial completed; CSR to the FDA August 2011; redacted IND submission to the FDA (FDA docket number FDA-2011-N-0918). PK re-analyses completed and submitted.  <b>Label changed as of December 24, 2014.</b>
Neonatal Seizures	No specific drug	Safety outcomes in medication exposure	Safety outcomes in neonates of mothers treated for seizure disorders	Co-fund with NINDS for Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic drugs (MONEAD) trial 2012-2014. <a href="https://web.emmes.com/study/monead/index.htm">https://web.emmes.com/study/monead/index.htm</a>
Apnea of Prematurity	Caffeine	Dosing and safety	Dosing and long-term safety of drug in preterm neonates	PPSR developed and submitted to agency.  NICHD co-fund of the Prematurity and Respiratory Outcomes Program (PROP)
<b>Exposure of medication in breastmilk</b>	<b>#Azithromycin</b>  <b>#Clindamycin</b>	<b>Dosing and safety</b>	<b>Opportunistic PK sampling of medications in mother-infant pairs</b>	<b>PTN study in development in collaboration with FDA</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

# Drugs listed twice for different indications or populations.

**Table 10. Adolescent Research Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Over-the-counter drug use	No specific drug	Health literacy		December 2007 symposium <a href="https://bpcanichd.nih.gov/collaborativeefforts/Documents/otc_drug_use_12-06-2007.pdf">https://bpcanichd.nih.gov/collaborativeefforts/Documents/otc_drug_use_12-06-2007.pdf</a>
Adolescent pharmacology	No specific drug	Effects of puberty on PK/ pharmacodynamics, adherence, and formulations research	Translational research, need to include adolescents in clinical trials	Pediatric Clinical Pharmacology Training grants thru NICHD and NIGMS co-funding <a href="https://bpcanichd.nih.gov/prioritization/working_groups/Documents/adolescent_wg_07-14-2009.pdf">https://bpcanichd.nih.gov/prioritization/working_groups/Documents/adolescent_wg_07-14-2009.pdf</a>
<b>Obesity</b>	<b>Weight loss system devices</b>	<b>Efficacy and safety</b>	<b>Collaborative research</b>	<b>Under consideration</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 11. Hematologic Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Sickle cell anemia	Hydroxyurea	Safety and efficacy in young children	PK, safety, and efficacy  Oral formulation for children	WR received from the FDA  BABY HUG trial completed in children 9–17 months of age, Draft CSR submitted in May 2013. Additional analyses underway  PK and bioavailability study conducted by PTN completed in December 2013 and submitted to FDA in February 2014  Long-term safety follow-up study under way
Thrombosis and thromboprophylaxis	Low-molecular-weight heparin	Treatment and prevention of childhood strokes and venous thrombosis	Determine validated biomarkers/surrogate markers of anticoagulant drug including developmental hemostasis parameters and age-appropriate assays  Adjunctive studies to evaluate toxicity	Pediatric opportunistic study in review by the PTN.

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 12. Endocrine Disease Priorities and Diseases with Limited Alternative Therapies**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Fragile X	MGluR5 antagonists	Outcome measures targets for intervention	Development of MGluR5 antagonists to treat Fragile X	Development of new therapeutics co-funded with <a href="https://bpca.nichd.nih.gov/collaborativeefforts/Documents/FragileX_children_05-08-2008.pdf">https://bpca.nichd.nih.gov/collaborativeefforts/Documents/FragileX_children_05-08-2008.pdf</a>
Type 1 diabetes	No specific drug	Immunomodulatory therapies	Development of novel immunomodulatory therapies for children with type 1 diabetes	Collaboration with sponsored NIH networks, including TrialNET and DirectNET. Funding completed  <b>Biomarkers of disease progress and treatment response working group in development</b>
<b>Metabolic syndrome</b>	<b>Metformin</b>	<b>Dosing and toxicity</b>	<b>PK and toxicity data</b>	<b>Under consideration</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 13. Dermatologic Diseases Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Severe inflammatory skin disease	#Methotrexate	Dosing, efficacy, and safety	Safety and efficacy in treatment of severe inflammatory disease	Co-fund of R13 workshop with NIAMS-2013 and 2014.
Hemangiomas	#Timolol	PK, safety, and efficacy	PK, safety	Opportunistic study completed.  <b>Clinical study of two doses of drug to start enrollment Winter 2017</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

#Drugs listed twice for different indications or populations.



**Table 14. Gastrointestinal Diseases Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Gastroesophageal reflux	Prokinetic drugs	Dosing, safety, and efficacy of existing drugs in neonates and infants	PK study	PTN Opportunistic study completed
	Pantoprazole	Dosing and efficacy data	Safety and effectiveness in infants	Pediatric PK/PD/Pharmacogenomics study completed. <b>CSR submitted to FDA in Spring 2017</b>
Inflammatory Bowel Disease	No specific drug	Safety and efficacy of treatments in children		Participation in Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT II & III) meetings
<b>Nausea and vomiting</b>	<b>Ondansetron</b>	<b>Dosing</b>	<b>PK studies in young children</b>	<b>Pediatric opportunistic study completed by the PTN. CSR in development</b>

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 15. Renal Diseases Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
<b>Chronic kidney disease</b>	No specific drug	<b>Pharmacoepidemiology data</b>	<b>Neurodevelopmental outcome assessments in children with CKD</b>	<b>Co-funding with NIDDK to evaluate outcomes of children with CKD.</b>
Acute kidney injury	No specific drug	Drug dosing, drug interactions	Population PK studies of multiple drugs used in this patient population to prevent sub-therapeutic dosing	PTN opportunistic study ongoing

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 16. Rheumatologic Disease Priorities**

<b>Current or Proposed Listed Therapeutic Area</b>	<b>Current or Proposed Listed Drug</b>	<b>Gaps in Knowledge/ Labeling</b>	<b>Type of BPCA Study and/or Scientific Needs</b>	<b>Plans and Progress</b>
Connective tissue disorders	Hydroxychloroquine	PK and safety in children with juvenile idiopathic arthritis	PK, safety studies	Under consideration

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.

**Table 17. Special Considerations**

Area of Consideration	Identified Therapeutic Area	Gaps in Knowledge/Labeling	Type of Study and/or Scientific Needs
Therapeutics in children with intellectual and developmental disabilities	No specific drug or indication	Identification of differences in drug disposition and response, including safety and efficacy outcome measures	Need for inclusion in clinical trials
Pediatric formulations	<p>Multiple drugs and indications:</p> <p>Infectious diseases:  HIV: antiretrovirals  Tuberculosis: isoniazid  Trypanosomiasis:  benznidazole  nifurtimox  Parasitic infections:  albendazole  Malaria:  mefloquine,  sulfadoxine-pyrimethamine  chlorproguanil-dapsone</p> <p>Hematology: hydroxyurea</p> <p>Oncology:  6-mercaptopurine  methotrexate  prednisone  isotretinoin</p> <p>Spasticity: baclofen</p> <p>Hypothyroidism: l-thyroxine</p> <p><b>Nitroglycerin Gel</b></p> <p><b>Surfactant</b></p>	<p>Taste-masking technologies</p> <p>Orally dissolvable dosage forms that do not require water</p> <p>Heat-stable and light-stable dosage forms</p> <p>Safety data for excipients</p> <p>New technology needed to improve water solubility of intravenous formulations, reducing the need for solvents</p> <p><b>Synthesis of existing data in use for ischemic or embolic events of peripheral vessels</b></p> <p><b>Aerosolized formulations</b></p>	<p>Improving the technology and designs of child-friendly/easy-to-swallow dosage forms of drugs to improve adherence and effectiveness</p> <p>NICHD-FDA Formulations Platform  <a href="https://bpea.nichd.nih.gov/prioritization/researchandcollaborations/Pages/pediatric-formulations-initiative.aspx">https://bpea.nichd.nih.gov/prioritization/researchandcollaborations/Pages/pediatric-formulations-initiative.aspx</a></p>
Pediatric devices	General Issues	Need for validation of existing devices used in children	Validation of existing methodologies
	Auto-injectors	Availability and validation of pediatric autoinjectors for biodefense countermeasures	Expansion of current methodologies, particularly in an emergency setting

Area of Consideration	Identified Therapeutic Area	Gaps in Knowledge/Labeling	Type of Study and/or Scientific Needs
<b>Opportunistic study of drugs used in children</b>	Multiple drugs: Alfentanil Amikacin Atropine Cefepime Ceftazidime Cidofovir Ciprofloxacin Clozapine Dexamethasone Digoxin Etomidate Haloperidol Lidocaine Lurasidone Methylprednisolone Molindone Nafcillin Nicardipine Olanzapine Pentobarbital Piperacillin-Tazobactam Quetiapine Rocuronium Tobramycin Vancomycin Vecuronium Warfarin Ziprasidone	Need for doing information on drugs used in children.	Dosing/PK data collected from patients previously prescribed drugs listed for different indications.  Data from this study may be used to develop full clinical studies and/or inform PK data for drug labels.

Drug and indications **in bold** have been identified by the NICHD as a priority and are newly added to the BPCA list.